Quest Diagnostics Q3: 7.7% Topline Decline, Earnings Beat, Updated Guidance & More

Quest Diagnostics Incorporated (NYSE: DGX) posted Q3 FY23 adjusted EPS of $2.22, down 5.9% Y/Y, beating the consensus of $2.19.

Sales came in at $2.295 billion, a decline of 7.7% Y/Y, higher than the Wall Street estimate of $2.27 billion.

COVID-19 testing revenues slumped 92% to $26 million, while Base business revenues improved ...

Full story available on

Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.

Disclaimer Press Release Banner